Pay in 4 interest-free payments of $5.40 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Oncotarget 7 , 1998219996 (2016)
The peptide therapeutics market is no longer a niche curiosity
The most common protocol error we observe isn't contamination or reconstitutionit's dosing frequency assumptions carried over from other peptide classes that don't apply to this particular compound's pharmacokinetic profile
We are no longer in a period of regulatory discretion. We are in a period of market consolidation through litigation. The pharmaceutical giants are no longer just making drugs
The enzyme capable of extending telomeric repeats the TTAGGG sequences that cap and protect chromosomal ends is transcriptionally repressed in most somatic cells after development
TXN, also referred to as TRX, acts as an enzyme that engages in the reduction of oxidized proteins through its redox-active site
US$ 20.35
US$ 21.26
US$ 25.74
US$ 26.59
US$ 25.77
US$ 24.24
